Anti-GD2 CAR-NKT Cells in Relapsed or Refractory Neuroblastoma: Updated Phase I Trial Interim Results

Investigators reported updated interim results from the first-in-human phase I evaluation of autologous natural killer T cells (NKTs) co-expressing a GD2-specific chimeric antigen receptors (CAR) with interleukin 15 in 12 children with neuroblastoma.